Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -373.0%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $4M | $108174 | $350977 | $708818 | $3M | $2M | $4M | $5M | $6M | $41895 |
| Enterprise Value | $-1322627 | $-1766255 | $-1009644 | $-4204666 | $-5565327 | $-13416496 | $-13109734 | $4M | $4M | $5M | $2M |
| P/E Ratio → | -0.18 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | 8.38 |
| P/B Ratio | 0.44 | 0.68 | 0.06 | 0.07 | 0.09 | 0.12 | 0.09 | 0.50 | 0.55 | 15.37 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | 330.20 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | 72.4% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -38430.4% |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | -6719.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -373.0% | -373.0% | -354.5% | -178.5% | -166.4% | -47.2% | -123.0% | -37.9% | -74.7% | -497.5% | — |
| ROA | -245.7% | -245.7% | -262.9% | -154.4% | -156.3% | -44.2% | -105.5% | -27.9% | -46.5% | -124.3% | -624.7% |
| ROIC | -3391.4% | -3391.4% | -1786.5% | -1054.3% | -296.1% | -107.6% | -140.2% | -35.7% | -83.1% | — | — |
| ROCE | -384.6% | -384.6% | -356.9% | -180.7% | -122.3% | -49.0% | -89.9% | -35.4% | -69.9% | -1248.8% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.04 | 0.03 | 0.03 | 0.00 | 0.01 | 0.13 | 0.02 | 6.56 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -0.66 | -0.91 | -0.84 | -0.64 | -0.66 | 0.04 | -0.16 | -1.07 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -31952.93 | -53.83 | -107.04 | -27.96 | -50.35 | -0.37 |
Net cash position: cash ($6M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.54 | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.03 |
| Quick Ratio | 2.54 | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.03 |
| Cash Ratio | 2.48 | 2.48 | 0.78 | 6.44 | 6.51 | 16.99 | 12.63 | 0.58 | 2.70 | 1.10 | 0.03 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | 1.54 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 14.7% | 0.0% | 54.9% | 2.1% | 4.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 14.7% | 0.0% | 54.9% | 2.1% | 4.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $122396 | $52463 | $32219 | $30639 | $14999 | $11051 | $10664 | $9313 | $1197 |
Critical liquidity and funding
According to recent market data, PCSA trades at a price-to-book ratio of 0.44, which, as reported in financial statements, suggests that the market is heavily discounting the company's assets due to the persistent uncertainty surrounding its ability to fund clinical development to completion.
The current P/B multiple of 0.44 indicates that the market values the company at a significant discount to its accounting book value, likely reflecting investor skepticism regarding the recoverability of its clinical assets. This valuation level suggests that the market is pricing in a high probability of further equity dilution or potential impairment of the pipeline's carrying value.
Based on the company's reported figures, ROE has plummeted to -83.2% in 2026Q1, a trend that, as indicated in historical filings, highlights the company's inability to generate positive returns on invested capital while it remains in a pre-revenue, cash-burning clinical development phase.
The consistent deterioration in ROE and ROIC over the last ten quarters underscores the structural challenge of funding long-term R&D without a commercial revenue stream. Investors should monitor whether these negative returns are merely a function of the development stage or if they indicate an inefficient allocation of capital across the company's broad, multi-indication pipeline.
As reported in financial statements, PCSA's current ratio has deteriorated significantly from a peak of 9.70 in 2024Q1 to 0.98 in 2026Q1, indicating that the company's ability to cover its short-term obligations is now severely constrained by the rapid exhaustion of its cash reserves.
The rapid decline in the current ratio suggests that the company's liquidity position has shifted from a position of relative comfort to one of extreme vulnerability. This trend warrants close investigation, as a current ratio near 1.0 leaves virtually no margin for error regarding unexpected clinical trial costs or delays in securing additional financing.
As indicated by the company's P/B ratio of 0.44, investors often rely on book value to gauge the floor for PCSA's valuation, which, as reported in recent filings, obscures the reality that intangible clinical assets may hold little liquidation value in a distress scenario.
The price-to-book ratio is frequently misapplied to clinical-stage biotechs because it assumes that the balance sheet assets have a tangible liquidation value. In the case of PCSA, the book value is heavily comprised of capitalized R&D and potential goodwill, which may be subject to significant impairment if clinical trials fail, making rNPV a more appropriate metric for assessing the company's true economic potential.
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PCSA stock.
Processa Pharmaceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Processa Pharmaceuticals, Inc.'s return on equity (ROE) is -373.0%. The historical average is -190.1%.
Based on historical data, Processa Pharmaceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.